在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

DPYD Antibody, Biotin conjugated

  • 中文名稱:
    DPYD兔多克隆抗體, Biotin偶聯(lián)
  • 貨號(hào):
    CSB-PA622516LD01HU
  • 規(guī)格:
    ¥880
  • 其他:

產(chǎn)品詳情

  • 產(chǎn)品名稱:
    Rabbit anti-Homo sapiens (Human) DPYD Polyclonal antibody
  • Uniprot No.:
  • 基因名:
    DPYD
  • 別名:
    DHP antibody; DHPDHase antibody; Dihydropyrimidine dehydrogenase [NADP(+)] antibody; Dihydropyrimidine dehydrogenase [NADP+] antibody; Dihydropyrimidine dehydrogenase antibody; Dihydrothymine dehydrogenase antibody; Dihydrouracil dehydrogenase antibody; DPD antibody; DPYD antibody; DPYD_HUMAN antibody; MGC132008 antibody; MGC70799 antibody; OTTHUMP00000058954 antibody
  • 宿主:
    Rabbit
  • 反應(yīng)種屬:
    Human
  • 免疫原:
    Recombinant Human Dihydropyrimidine dehydrogenase [NADP(+)] protein (5-152AA)
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標(biāo)記方式:
    Biotin
  • 克隆類型:
    Polyclonal
  • 抗體亞型:
    IgG
  • 純化方式:
    >95%, Protein G purified
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
  • 產(chǎn)品提供形式:
    Liquid
  • 應(yīng)用范圍:
    ELISA
  • Protocols:
  • 儲(chǔ)存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能:
    Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.
  • 基因功能參考文獻(xiàn):
    1. This study reports novel and rare genetic variants underlying DPD deficiency in 9 cancer patients presenting with severe fluoropyrimidine-associated toxicity. PMID: 28024938
    2. TYMS 2R3R polymorphism and the -[IVS]14+1G>A mutation in DPYD was not associated with susceptibility to CRC. However, the 2R/2R and 2R/3R genotypes of TYMS polymorphism could significantly contribute to hematological and gastric toxicity in CRC patients in this sample populatio PMID: 29906295
    3. Results still showed UGT1A1*6 and UGT1A1*28 to be partially associated with irinotecan-induced toxicity and clinical response. An examination of more UGT1A loci, except for UGT1A1*6 and UGT1A1*28, was not helpful to improve the predictive value of irinotecan-based toxicity and efficacy. An examination of DPYD*5 assisted in the prediction of severe diarrhea. PMID: 28637434
    4. The present study suggests that the SNP rs1801160 and the "IISt" haplotype in the DPYD gene may also have a role in colorectal cancer risk. PMID: 29372689
    5. Low DPYD expression is associated with colorectal cancer. PMID: 28929491
    6. *6 rs1801160 and *2A rs3918290 DPYD variant alleles were significantly associated with time to neutropenia in colon cancer. PMID: 29065426
    7. Results have shown crosstalk among the EGFR cascade and Sp1 and DPD expressions in EGFR mutant non-small-cell lung cancer cell lines. EGF-induced Sp1 up-regulation resulted in both DPYD mRNA and DPD protein expressions. PMID: 27268079
    8. Carriers of the rare allelic variants DPYD*2A, DPYD*13, and DPYD D949V are more likely to experience severe adverse reactions during fluoropyrimidine-based therapy. PMID: 28614820
    9. Exploring an extended set of deleterious DPYD variants improves the performance of DPYD genotyping for predicting both grade 3-4 and grade 4 toxicities (digestive and/or neurologic and/or hematotoxicities) related to capecitabine, as compared to conventional genotyping restricted to consensual variants *2A, *13 and D949V PMID: 28481884
    10. Combined expression analyses of hENT1, TS, and DPD may predict long-term outcomes in patients with borderline resectable pancreatic cancer after neoadjuvant chemoradiotherapy PMID: 28476815
    11. We demonstrated that real-time DPYD genotyping using TaqMan probes is cost effective in all fluoropyrimidine-based treatments PMID: 27248859
    12. In pancreatic neuroendocrine neoplasms, biochemical response (p = 0.005) and high dihydropyrimidine-dehydrogenase expression (p = 0.018) were predictive markers of response to 5-FU-based chemotherapy. Thymidylate-Synthase deficiency was an independent risk factor for shorter progression-free survival. PMID: 28027897
    13. ERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer. PMID: 27741011
    14. this study was to identify potential risk variants in DPYP gene in an understudied East African population as predictors of severe adverse toxicity to 5-FU PMID: 27727460
    15. Fourteen out of 275 cancer patients (5.1%) carried a DPYD variant and received a 25-50% dose reduction recommendation for 5-fluorouracil or capecitabine. None of the patients with a DPYD variant treated with a reduced dose developed toxicities. PMID: 27181275
    16. findings showed that almost 57.1% of Chinese colorectal cancer patients had at least one variant of DPYD*5A and DPYD*9A PMID: 27461651
    17. High levels of intratumoral DPD expression have a negative impact on sensitivity to 5-fluorouracil in gastric cancer patients, but no prognostic value for long-term survival was uncovered. (Meta-analysis) PMID: 28255193
    18. Reprot strong functional effect of a DPYD haplotype upon a phenotypic marker of individual 5-FU metabolism to improve toxicity prediction. PMID: 26216193
    19. we believe that developing functional testing at the bedside could probably help to better picture the actual DPD status of patients scheduled for fluorouracil-based therapy, so as to propose subsequent appropriate adaptive dosing strategies. PMID: 27281624
    20. DPYD genotyping for alleles 7, *2A, *13 and Y186C was not helpful in the identification of patients with severe DPD deficiency in this series of patients PMID: 27399164
    21. Our results revealed that the C allele of the DPYD 85T > C polymorphism might be associated with susceptibility to pediatric acute lymphoblastic leukemia PMID: 26846104
    22. Increases in gene expression levels of TYMP, DPYD, and HIF1A in tumor tissues at 7 days after the start of CRT may be useful for predicting the efficacy of CRT including S-1 or UFT PMID: 27127154
    23. There were not statistical significant differences between carriers of KRAS mutated alleles between SD and PD groups. No significant difference was found between response rates and toxicity and DPD or UGT1A1 genotypes. Our results suggested that determination of DPD or UGT1A1 genotypes could not be useful for predicting severe toxicity of irinotecan in our population. PMID: 27072236
    24. Study shows that somatic mutations of DPYD cause a switch in pyrimidine metabolism and promote gene expression of pyrimidine enzymes toward malignant progression. PMID: 26609109
    25. Results suggest that DPYD c.1129-5923 C>G/hapB3 have limited predictive value for severe toxicity to 5-FU based combination chemotherapy. PMID: 26658227
    26. oxaliplatin-based chemotherapy increases ERCC1 and DPYD expression levels; bevacizumab induces VEGFA expression in metastatic colorectal cancer PMID: 26372896
    27. This study demonstrates the clinical validity of combined MIR27A/DPYD screening to identify patients at risk of severe FP-toxicity. PMID: 26804235
    28. The expression of dihydropyrimidine dehydrogenase and its correlation with survival in stage II/III gastric cancer patients PMID: 25112781
    29. We propose the gene activity score for translating DPYD genotype into phenotype--{REVIEW} PMID: 26265346
    30. Demonstrate a correlation between occurrence of DPYD gene variant c.496A>G and KRAS wild type status of colorectal cancer tissue. PMID: 26281864
    31. Single nucleotide polymorphisms (SNPs) in Dihydropyrimidine Dehydrogenase and UGT1A1 influence fluoropyrimdines and irinotecan adverse events (AEs). PMID: 25782327
    32. The relationship between DPD genotype and dihydrouracil/uracil values in the 22 patients of the present study was significant PMID: 26265035
    33. DPYD variants c.1679T>G and c.1236G>A/HapB3 are clinically relevant predictors of fluoropyrimidine-associated toxicity. PMID: 26603945
    34. The dihydropyrimidine dehydrogenase and ERCC1 expression profile could potentially serve as a useful prognostic biomarker and therapeutic target for surgically resected patients with ampullary carcinoma. PMID: 25906447
    35. miR-494 is directly bound to DPYD 3'UTR and negatively regulated DPYD expression in colon cancer. PMID: 25873402
    36. results suggest that the baseline 5,6-dihydrouracil:uracil plasma ratio in most individuals reflects the nonsaturated state of DPD and is not predictive of decreased DPD activity PMID: 25410891
    37. genome-wide association studies in women of European ancestry: Data confirm that SNPs in DPYD (rs11587873, rs828054) are associated with ovarian carcinoma; analyses included over 36,000 women contributing DNA in the Ovarian Cancer Assoc Consortium. PMID: 25066213
    38. Germline polymorphism of DPYD have a significant effect on toxicity and clinical outcome in patients receiving capecitabine-based chemotherapy for metastatic gastrointestinal malignancies. PMID: 25677447
    39. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor and response to chemotherapy. PMID: 24405586
    40. In patients with heterozygous DPD IVS14+1 mutation, 5-FU dose should be appropriately reduced according to last plasma concentration to reduce adverse reactions, while the homozygous ones should avoid application of 5-FU and its derivatives. PMID: 24817302
    41. DPYD harbours rare and common capecitabine toxicity variants PMID: 24647007
    42. Pre-therapeutic DPYD testing may prevent 20-30% of life-threatening or lethal episodes of fluoropyrimidine toxicity in Caucasian patients PMID: 24923815
    43. Taken together, these results suggest that miR-27a and miR-27b expression may be pharmacologically relevant modulators of Dihydropyrimidine dehydrogenase enzyme function in the liver. PMID: 24401318
    44. We suggest that a chip including DPYD, TYMS, TYMP, TK1, and TK2 genes is a potential tool to predict response in LARC following fluoropyrimidine-based CCRT. PMID: 24455740
    45. Colorectal tumors, deficient in mismatch repair, overexpress thymidylate synthetase and dihydropyrimidine dehydrogenase. PMID: 24800948
    46. Association between flurouracil toxicity and DPYD missense mutations. PMID: 24648345
    47. DPD is involved in the survival of human embryo brain-derived cells in culture. There was a a reversed correlation between the activities of XO and DPD over 12 days under normal conditions as well as in the presence of XO and DPD inhibitors. PMID: 23597150
    48. Of 36 previously assessed polymorphisms, only four-TYMS 5'VNTR 2R/3R, TYMS 3'UTR 6bpins-del, DPYD 2846TA, and DPYD *2A-were formally associated with global G3+ toxicity in our analysis. Associations were only present in fluorouracil monotherapy regimens. PMID: 24590654
    49. DPYD*5 and 1896 T>C accounted for 29.9% of the occurrences of neutropenia (analysis of variance, P = 0.017). PMID: 23942539
    50. One nonsynonymous SNP of Dihydropyrimidine dehydrogenase (+199381A > G, Asn151Asp) was predicted to change its polarity of amino acid (Asn, neutral to Asp, negative). PMID: 23960437

    顯示更多

    收起更多

  • 相關(guān)疾病:
    Dihydropyrimidine dehydrogenase deficiency (DPYDD)
  • 亞細(xì)胞定位:
    Cytoplasm.
  • 蛋白家族:
    Dihydropyrimidine dehydrogenase family
  • 組織特異性:
    Found in most tissues with greatest activity found in liver and peripheral blood mononuclear cells.
  • 數(shù)據(jù)庫(kù)鏈接:

    HGNC: 3012

    OMIM: 274270

    KEGG: hsa:1806

    STRING: 9606.ENSP00000359211

    UniGene: Hs.335034



主站蜘蛛池模板: 日韩人妻无码中文字幕视频| 国产无限次数成版人视频在线 | 国产熟妇另类久久久久久| 国产精品无码av不卡顿| 欧美 日韩 国产 成人 在线观看| 国产精品久久久久永久免费看| 在线亚洲日产一区二区| 中老年熟妇激情啪啪大屁股| 熟女少妇丰满一区二区| 久久人人妻人人做人人爽| 亚洲精品无码久久千人斩| 国产成人欧美日韩在线电影| 欧美性白人极品1819hd| 国产妇女馒头高清泬20p多毛| 日韩无套内射视频6| 99久久九九社区精品| 毛片免费视频在线观看| 天堂中文最新版在线中文| 久久综合久久88中字幕文| 亚洲中文无码人a∨在线| 日日碰狠狠躁久久躁婷婷 | 冲田杏梨av一区二区三区| 精品无人区麻豆乱码1区2区| 男人j进女人p免费视频| 狠狠做五月深爱婷婷伊人 | 麻豆自媒体 一区 二区| 制服丝袜亚洲欧美中文字幕| 1000部拍拍拍18勿入免费视频| 80s国产成年女人毛片| 高清国产一区二区三区在线| 少妇久久久久久人妻无码| 日韩a∨精品日韩在线观看| www插插插无码视频网站| 成人美女黄网站色大色费全看| 国产成人久久综合第一区| 精品国产sm最大网免费站| 很色很爽很黄裸乳视频| 午夜肉伦伦影院| 亚洲国产精品一区二区www| 国模少妇一区二区三区| 欧洲丰满少妇a毛片|